Patent · US Active

Glyco-engineered antibodies

US9051577B2 · kind B2 · utility

1Cited by

1References

19Claims

0Family size

Assignee

GREENOVATION BIOTECH GMBH · DE

Inventors

Manfred Schuster · Schrick, AT
Ralf Kircheis · Wien, AT
Andreas Nechansky · Oberwaltersdorf, AT
Wolfgang Jost · Glückstadt, DE
Gilbert Gorr · Glückstadt, DE

Key dates

Filing date	Jul 11, 2007
Grant date	Jun 9, 2015
Priority date	—
Expiry date	Apr 27, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.